Consun Pharmaceutical Group (HKSE:01681) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Consun Pharmaceutical Group LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Consun Pharmaceutical Group's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Consun Pharmaceutical Group's long-term debt to total assets ratio stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Consun Pharmaceutical Group LT-Debt-to-Total-Asset Historical Data

The historical data trend for Consun Pharmaceutical Group's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Consun Pharmaceutical Group LT-Debt-to-Total-Asset Chart

Consun Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Consun Pharmaceutical Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Consun Pharmaceutical Group LT-Debt-to-Total-Asset Calculation

Consun Pharmaceutical Group's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	4.264	/	6024.528
	=	0.00

Consun Pharmaceutical Group's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	4.264	/	6024.528
	=	0.00

Consun Pharmaceutical Group (HKSE:01681) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Consun Pharmaceutical Group LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Consun Pharmaceutical Group's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Consun Pharmaceutical Group (HKSE:01681) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Consun Pharmaceutical Group Ltd (HKSE:01681) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

C1P:Germany

Address

71, Dongpeng Avenue, Eastern section, Guangzhou Economic and Technological Development, Guangzhou, CHN

Website

https://www.chinaconsun.com

Consun Pharmaceutical Group Ltd is a biotechnology company with sales operations throughout China. Its principal activities are making and selling pharmaceutical products. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.

Executives

An Yubao	2101 Beneficial owner
Li Qian	2101 Beneficial owner
Central Success Developments Limited	2101 Beneficial owner
Aali Resources Limited	2201 Interest of corporation controlled by you
Bos Trustee Limited	2301 Trustee
Zhang Lihua	2202 Interest of your spouse
An Meng	2101 Beneficial owner
Double Grace International Limited	2101 Beneficial owner
Bos Trustee Limited As Trustee	2201 Interest of corporation controlled by you

Consun Pharmaceutical Group (HKSE:01681) Headlines

No Headlines